ArticleMolecular biology reports2026
STAT3-mediated suppression of the pre-induction silencer Ets-2 in activated T helper cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin-2 (IL-2) is the first cytokine produced by naive T helper (Th) cells after antigen recognition and is essential for initiating Th cell proliferation and differentiation. We previously identified the transcription factor Ets-2 as a pre-induction silencer of IL-2, showing that its downregulation upon Th cell activation permits IL-2 transcription. However, the upstream mechanisms regulating Ets-2 expression remain undefined. Given the central role of STAT family transcription factors in Th cell gene regulation, we investigated whether STAT signaling controls Ets-2 transcription. METHODS AND
resultsBioinformatic analysis identified STAT binding motifs within the Ets-2 promoter. Using the Jurkat T cell line as a model, we examined changes in STAT3, Ets-2, and IL-2 expression following cell activation. STAT3 function was assessed through overexpression and knockdown experiments, with Ets-2 mRNA and protein levels measured by real-time PCR and western blotting. Chromatin immunoprecipitation was used to determine direct binding of STAT3 to the Ets-2 promoter. Our results showed that cell activation led to increased STAT3 mRNA and protein expression, accompanied by reduced Ets-2 expression and enhanced IL-2 production. STAT3 overexpression significantly decreased Ets-2 mRNA and protein levels, whereas STAT3 knockdown resulted in increased Ets-2 expression. Chromatin immunoprecipitation demonstrated direct binding of phosphorylated STAT3 (Tyr705) to the Ets-2 promoter.
conclusionsSTAT3 acts as a negative regulator of Ets-2 transcription in Th cells through direct binding in its phosphorylated form to the Ets-2 promoter, establishing a causal suppressive pathway linking STAT3 activation to IL-2 de-repression.
Indexed as
Identifiers
42684610What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.